Compare GAUZ & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAUZ | VTYX |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 713.6M |
| IPO Year | 2024 | 2021 |
| Metric | GAUZ | VTYX |
|---|---|---|
| Price | $1.20 | $8.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $11.50 | ★ $14.60 |
| AVG Volume (30 Days) | 328.3K | ★ 1.7M |
| Earning Date | 03-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $96,810,000.00 | N/A |
| Revenue This Year | $22.59 | N/A |
| Revenue Next Year | $47.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.87 | N/A |
| 52 Week Low | $1.10 | $0.78 |
| 52 Week High | $13.00 | $10.55 |
| Indicator | GAUZ | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 23.86 | 47.12 |
| Support Level | $1.10 | $8.39 |
| Resistance Level | $2.69 | $9.13 |
| Average True Range (ATR) | 0.30 | 0.63 |
| MACD | 0.04 | -0.25 |
| Stochastic Oscillator | 6.29 | 20.35 |
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.